Teva Pharmaceutical Industries (NYSE:TEVA) PT Raised to $25.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective raised by equities research analysts at Barclays from $22.00 to $25.00 in a report released on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 37.02% from the company’s current price.

Several other equities analysts have also recently issued reports on the stock. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Jefferies Financial Group increased their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. UBS Group raised their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday. Finally, Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Wednesday, July 10th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Down 0.9 %

NYSE TEVA opened at $18.25 on Wednesday. Teva Pharmaceutical Industries has a 1 year low of $8.10 and a 1 year high of $19.08. The stock has a market capitalization of $20.67 billion, a PE ratio of -44.50, a PEG ratio of 1.32 and a beta of 0.88. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The business’s 50-day moving average is $18.02 and its 200 day moving average is $16.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 24,537 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at $777,285. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.55% of the stock is owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently bought and sold shares of the business. New Covenant Trust Company N.A. bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth approximately $28,000. EntryPoint Capital LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter worth approximately $30,000. UMB Bank n.a. grew its position in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $48,000. Finally, Byrne Asset Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at $52,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.